RCM
NVAX icon

Raleigh Capital Management’s Novavax NVAX Stock Holding History

Raleigh Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$16 – 872
2024
Q4 		$16 Hold
2
– – ﹤0.01% 1018
2024
Q3 		$25 Hold
2
– – ﹤0.01% 989
2024
Q2 		$25 Hold
2
– – ﹤0.01% 980
2024
Q1 		$10 Hold
2
– – ﹤0.01% 959
2023
Q4 		$10 Hold
2
– – ﹤0.01% 1078
2023
Q3 		$14 Hold
2
– – ﹤0.01% 950
2023
Q2 		$15 Hold
2
– – ﹤0.01% 833
2023
Q1 		$14 Hold
2
– – ﹤0.01% 837
2022
Q4 		$20 Hold
2
– – ﹤0.01% 764
2022
Q3 		$0 Hold
2
– – ﹤0.01% 828
2022
Q2 		$0 Hold
2
– – ﹤0.01% 638
2022
Q1 		$0 Buy
+2
New +$178 ﹤0.01% 657

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raleigh Capital Management's NVAX Position: Q1 2025 in Review

Raleigh Capital Management sold out of Novavax (NVAX) in Q1 2025, closing a stake of 2 shares — an estimated $16 sold.

Raleigh Capital Management first reported a position in NVAX in Q1 2022 and held it in 12 quarters. The position peaked at $25 in Q3 2024. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Raleigh Capital Management reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 2 Novavax shares in Q1 2025, an estimated $16.
  • Raleigh Capital Management first reported a position in Novavax in Q1 2022 and held it in 12 quarters.
  • Raleigh Capital Management's Novavax position peaked at $25 in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.